Literature DB >> 2189310

Disulfiram treatment of alcoholism.

C Wright1, R D Moore.   

Abstract

PURPOSE: For 40 years, disulfiram has been the alcohol-aversive drug used most frequently by American physicians in the treatment of alcohol dependency disorders. We reviewed the clinical literature regarding the risks, benefits, indications, and efficacy of this controversial drug and summarized current knowledge of this therapy.
CONCLUSIONS: Disulfiram will produce an aversive reaction with ethanol, usually at a dose between 250 mg/day and 500 mg/day, although some patients may not have an aversive reaction at this level. Cardiac, hepatic, and neurologic toxicity can also occur within this dosage range. If disulfiram is to be used, the patient must clearly understand the risks of drinking while taking the drug, and the physician and patient must agree about the need for continued clinical supervision and monitoring for efficacy and side effects. The physician must also recognize that disulfiram is only an adjunctive therapy and that continued support, supervision, and other therapeutic measures are required. Disulfiram is probably effective in reducing the frequency of alcohol consumption in the compliant patient over the short term (e.g., 6 months). Certain subgroups of patients, such as those who are older, those who are more socially stable, and those who are well-motivated, may experience a beneficial effect for longer periods. The drug may be most effective in reducing short-term alcohol consumption when the compliance of the patient is supervised, although consideration of this kind of therapy includes the practical problems of supervising the patient and concerns that the supervising person may be placed in a difficult position. Prescription of disulfiram without accompanying education, counseling, and concomitant alcoholism therapy is not beneficial. Disulfiram has no proven effect on the long-term outcome of alcoholism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189310     DOI: 10.1016/0002-9343(90)90534-k

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  52 in total

1.  Proteasome inhibitor treatment in alcoholic liver disease.

Authors:  Fawzia Bardag-Gorce
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Disulfiram Use in an Elderly Man With Alcoholism and Heart Disease: A Discussion.

Authors:  Jeff C. Huffman; Theodore A. Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

3.  The Repurposed Drug Disulfiram Inhibits Urease and Aldehyde Dehydrogenase and Prevents In Vitro Growth of the Oomycete Pythium insidiosum.

Authors:  Theerapong Krajaejun; Tassanee Lohnoo; Wanta Yingyong; Thidarat Rujirawat; Yothin Kumsang; Passara Jongkhajornpong; Sirin Theerawatanasirikul; Weerayuth Kittichotirat; Onrapak Reamtong; Hanna Yolanda
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Disulfiram effects on responses to intravenous cocaine administration.

Authors:  Jennifer R Baker; Peter Jatlow; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

Review 5.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

6.  Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.

Authors:  Elinore F McCance-Katz; Valerie A Gruber; George Beatty; Paula Lum; Qing Ma; Robin DiFrancesco; Jill Hochreiter; Paul K Wallace; Morris D Faiman; Gene D Morse
Journal:  Am J Addict       Date:  2013-10-11

Review 7.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

8.  Disulfiram-based disulfides as narrow-spectrum antibacterial agents.

Authors:  Jordan G Sheppard; Keely R Frazier; Pushkar Saralkar; Mohammad F Hossain; Werner J Geldenhuys; Timothy E Long
Journal:  Bioorg Med Chem Lett       Date:  2018-03-10       Impact factor: 2.823

9.  Combination of Disulfiram and Copper-Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer.

Authors:  Yan Chang; Fang Wu; Nil Kanatha Pandey; Lalit Chudal; Meiying Xing; Xiaoli Zhang; Linh Nguyen; Xian Liu; J Ping Liu; Wei Chen; Zui Pan
Journal:  ACS Appl Bio Mater       Date:  2020-09-09

Review 10.  Neurologic effects of alcoholism.

Authors:  I Diamond; R O Messing
Journal:  West J Med       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.